Skip to main content

TFF Pharmaceuticals, Inc.

TFFPDelisted Mar 6, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001733413

TFF Pharmaceuticals, Inc. was delisted on Mar 6, 2025; its insiders filed their last Form 4 on Jul 8, 2024; 23 institutions reported holding it in 13F filings for Q3 2024, worth $1.48M in total; no superinvestor held it.

Holders of 5% or more of TFFP

Holders whose latest Schedule 13D or 13G filing reports 5% or more of TFF Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of TFF Pharmaceuticals, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

3 Schedule 13D and 13G filings on TFF Pharmaceuticals, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on TFFP
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 14, 2023Lung Therapeutics, Inc.13G/AOld format–––SEC
Feb 13, 2023Lytton Laurence W13G/AOld format–––SEC
Feb 9, 2023Carlson Capital L P13G/AOld format–––SEC
Nov 28, 2022Carlson Capital L P13GOld format–New–SEC
Nov 23, 2022Lytton Laurence W13GOld format–New–SEC
Feb 14, 2022Lung Therapeutics, Inc.13G/AOld format–––SEC
Feb 14, 2022Corriente Advisors, LLC13G/AOld format–––SEC
Feb 14, 2022Nantahala Capital Management, LLC13G/AOld format–––SEC
Feb 16, 2021Corriente Advisors, LLC13GOld format–New–SEC
Feb 16, 2021Nantahala Capital Management, LLC13GOld format–New–SEC
Feb 3, 2021Lung Therapeutics, Inc.13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell TFF Pharmaceuticals, Inc. shares.

No Form 144 notices for TFF Pharmaceuticals, Inc. are on file.